文献速递炎症性肠病消化道肿瘤与早癌

克罗恩病患者按治疗状态划分的恶性肿瘤绝对风险:全国性人群队列研究

Absolute Risk of Malignancy by Treatment in Patients With Crohn's Disease Compared with the General Population: A Nationwide Population-Based Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2026-08-26

该研究基于瑞典全国登记数据,纳入2007—2023年38,733例克罗恩病患者及360,616名对照,中位随访7.3年,评估不同治疗状态下总体及分类型癌症的绝对发病风险。结果显示所有治疗队列(包括未使用免疫调节剂者)总体癌症发病率均高于一般人群,超额主要来自非黑色素瘤皮肤癌;排除皮肤癌后超额约1例/1000人年,与肺癌、小肠癌、肝胆癌和血液系统肿瘤相关。

要点

  • 所有治疗队列(含未用免疫调节剂者)总体癌症发病率均高于匹配人群。
  • 超额癌症主要来自非黑色素瘤皮肤癌(鳞癌和基底细胞癌)。
  • 排除皮肤癌后,超额约1例/1000人年,与肺癌、小肠癌、肝胆癌和血液肿瘤相关。

核心结论

  • 克罗恩病患者各治疗队列(包括未使用免疫调节剂者)总体癌症发病率均高于一般人群。
  • 排除非黑色素瘤皮肤癌后,超额癌症发病约1例/1000人年,与肺癌、小肠癌、肝胆癌和血液系统肿瘤相关。

研究设计与样本

  • 基于瑞典全国登记数据的全国性人群队列研究,链接2007—2023年克罗恩病患者数据。
  • 采用一旦暴露始终暴露设计,按年龄分层估计与一般人群的发病率差。
  • 随访38,733例患者和360,616名对照,中位随访7.3年。
  • 治疗队列包括噻嘌呤、TNF抑制剂、噻嘌呤+TNF抑制剂、维得利珠单抗、乌司奴单抗新使用者及未使用免疫调节剂者。

主要发现

  • 任何癌症的发病率差(各治疗队列每1000人年较匹配人群的超额癌症数):未治疗队列2.43(95%CI:1.92;2.94)。
  • 噻嘌呤治疗者3.14(95%CI:2.50;3.78),TNF抑制剂治疗者2.42(95%CI:1.63;3.22)。
  • 噻嘌呤+TNF抑制剂2.59(95%CI:1.53;3.64),维得利珠单抗2.61(95%CI:-0.08;5.30),乌司奴单抗1.54(95%CI:-1.34;4.41)。
  • 超额癌症主要来自非黑色素瘤皮肤癌(鳞状细胞癌和基底细胞癌)。
  • 排除非黑色素瘤皮肤癌后,未治疗、噻嘌呤和TNF抑制剂组的超额总体癌症发病为1.27至0.96例/1000人年,其他组未显著增加。

关键数值与推荐

  • 任何癌症发病率差:未治疗队列2.43(95%CI:1.92;2.94)/1000人年。
  • 噻嘌呤3.14(95%CI:2.50;3.78)、TNF抑制剂2.42(95%CI:1.63;3.22)、联合治疗2.59(95%CI:1.53;3.64)/1000人年。
  • 维得利珠单抗2.61(95%CI:-0.08;5.30)、乌司奴单抗1.54(95%CI:-1.34;4.41)/1000人年。
  • 排除非黑色素瘤皮肤癌后,未治疗、噻嘌呤和TNF抑制剂组超额总体癌症发病为1.27至0.96例/1000人年。

临床怎么用

  • 为克罗恩病患者咨询癌症风险时,应告知所有治疗状态(包括未用免疫调节剂)总体癌症风险均高于一般人群。
  • 应重视非黑色素瘤皮肤癌的监测与防晒教育。
  • 排除皮肤癌后超额风险约1例/1000人年,可结合肺癌、小肠癌、肝胆癌和血液肿瘤风险进行个体化随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Real-world data quantifying absolute cancer risk in Crohn's disease (CD) by treatment status are lacking but are essential for patient counselling. METHODS: We linked nationwide Swedish register data and assessed incident cancers overall and by type in patients with CD 2007-2023. We estimated age-stratified incidence rate (IR) differences compared with the general population in a once-exposed-always-exposed design. Treatment cohorts comprised new users of thiopurine, tumor necrosis factor inhibitors (TNFi), thiopurine + TNFi, vedolizumab, ustekinumab, and patients naïve to immunomodulatory drugs. RESULTS: We followed 38,733 patients and 360,616 comparator subjects for a median 7.3 years. The IR differences for any cancer (number of excess cancers in each treatment cohort per 1,000 person-years versus the matched population) were 2.43 (95% CI: 1.92; 2.94) for the naive cohort; 3.14 (95% CI: 2.50; 3.78) for thiopurine-treated, 2.42 (95% CI: 1.63; 3.22) for TNFi-treated, 2.59 (95% CI: 1.53; 3.64) for thiopurine + TNFi, 2.61 (95% CI: -0.08; 5.30) for vedolizumab, and 1.54 (95% CI: -1.34; 4.41) for ustekinumab. The excess cancer incidence was primarily because of nonmelanoma skin cancer (squamous cell and basal cell carcinoma). After exclusion of nonmelanoma skin cancers, the excess overall cancer incidence was 1.27 to 0.96 cases/1,000 person-years in the naïve, thiopurine, and TNFi-treated groups, but not significantly increased in the other. IR differences for overall cancer increased and hazard ratios decreased with increasing patient age. DISCUSSION: Elevated overall cancer incidence was observed across all treatment cohorts, also in treatment-naïve patients. After exclusion of nonmelanoma skin cancer, the excess cancer incidence in CD was around 1 extra case per 1,000 person-years because of lung, small bowel, hepatobiliary, and hematologic cancers.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Everhov ÅH, Eriksson J, Söderling J, et al. Absolute Risk of Malignancy by Treatment in Patients With Crohn's Disease Compared with the General Population: A Nationwide Population-Based Cohort Study. Am J Gastroenterol. 2026. PMID: 42467952. doi:10.14309/ajg.0000000000004119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。